Atlas Trials

A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

Clinical trial NCT02672501 · UNKNOWN

Trial details

NCT number
NCT02672501
Sponsor
Shanghai GeneChem Co., Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Leukemia, B-Cell
Start date
2016-01-01
Primary completion
2018-06-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.